RxDoctor Payments Data

Polly Klement, NP

Nurse Practitioner · Valley View, TXNPI 1437440039

Payments from drug & device makers

$448in general payments, 2019–2025

Across 21 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$195
  • Lilly USA, LLC$88
  • Exact Sciences$37
  • Myriad Women's Health, Inc.$22
  • Astellas Pharma US Inc$22
  • Novo Nordisk$16
  • plus $67 from 5 others

What the payments were for

  • Food & beverage$448100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$448 in reported general payments places this provider in the 65th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$37,778
Medicare patients
209
Services billed
780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate36$21,649
MounjaroTirzepatide12$12,979
JardianceEmpagliflozin18$12,842
OzempicSemaglutide13$12,066
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,106
EliquisApixaban15$6,274
Levothyroxine Sodium150$1,287
Liothyronine Sodium47$1,198
Gabapentin51$1,111
Albuterol Sulfate HfaAlbuterol Sulfate44$993
HumalogInsulin Lispro13$811
Potassium Chloride45$610
Temazepam44$579
Lisinopril91$558
Buspirone Hcl56$536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Humalog$88$13,79025 claims
Novo NordiskOzempic$16$12,06613 claims
GSKTrelegy Ellipta$13$11,10614 claims
AbbVieSynthroid$195$30813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Valley View

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →